Prelude Capital Management’s Insys Therapeutics, Inc. INSY Stock Holding History

Prelude Capital Management’s Portfolio INSY Stock Details INSY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-486	Closed	-$2K	–	2377
2018 Q4	$2K	Hold	486	–	–	﹤0.01%	1702
2018 Q3	$5K	Sell	486 -136	-22%	-$1.08K	﹤0.01%	1639
2018 Q2	$5K	Sell	622 -218	-26%	-$1.52K	﹤0.01%	1565
2018 Q1	$5K	Buy	840 +204	+32%	+$1.68K	﹤0.01%	1423
2017 Q4	$6K	Sell	636 -6	-0.9%	-$39	﹤0.01%	1258
2017 Q3	$6K	Sell	642 -402	-39%	-$4.15K	﹤0.01%	1498
2017 Q2	$13K	Buy	+1,044	New	+$12.4K	﹤0.01%	1355
2017 Q1	–	Sell	-2,600	Closed	-$24K	–	1917
2016 Q4	$24K	Sell	2,600 -1,600	-38%	-$18.1K	﹤0.01%	1287
2016 Q3	$50K	Buy	+4,200	New	+$63.8K	0.01%	1046
2016 Q1	–	Sell	-2,100	Closed	-$60K	–	1663
2015 Q4	$60K	Buy	2,100 +800	+62%	+$22.2K	0.01%	1007
2015 Q3	$37K	Sell	1,300 -800	-38%	-$29.4K	0.01%	1135
2015 Q2	$75K	Buy	2,100 +500	+31%	+$15.6K	0.01%	997
2015 Q1	$47K	Sell	1,600 -5,200	-76%	-$138K	0.01%	1321
2014 Q4	$143K	Hold	6,800	–	–	0.02%	860
2014 Q3	$132K	Sell	6,800 -3,200	-32%	-$50.3K	0.02%	933
2014 Q2	$156K	Buy	+10,000	New	+$162K	0.02%	849

Other funds holding INSY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

RCM

Raging Capital Management Rocky Hill, New Jersey $18.2M AUM 17.75% 1-Year Est. Return

Prelude Capital Management's INSY Position: Q1 2019 in Review

Prelude Capital Management sold out of Insys Therapeutics, Inc. (INSY) in Q1 2019, closing a stake of 486 shares — an estimated $2K sold.

Prelude Capital Management first reported a position in INSY in Q2 2014 and held it in 16 quarters. The position peaked at $156K in Q2 2014. 98 funds tracked by Wall St. Rank hold INSY as of Q1 2019.

Prelude Capital Management reported no remaining Insys Therapeutics, Inc. position as of Q1 2019 after selling out during the quarter.
Prelude Capital Management sold 486 Insys Therapeutics, Inc. shares in Q1 2019, an estimated $2K.
Prelude Capital Management first reported a position in Insys Therapeutics, Inc. in Q2 2014 and held it in 16 quarters.
Prelude Capital Management's Insys Therapeutics, Inc. position peaked at $156K in Q2 2014.
98 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q1 2019.

Based on Prelude Capital Management's 13F filing for Q1 2019, filed 15 May 2019.